JP2012529293A - 微粒子の分泌を阻害することによりエイズまたは癌を治療することを目的とした組成物および方法 - Google Patents

微粒子の分泌を阻害することによりエイズまたは癌を治療することを目的とした組成物および方法 Download PDF

Info

Publication number
JP2012529293A
JP2012529293A JP2012514976A JP2012514976A JP2012529293A JP 2012529293 A JP2012529293 A JP 2012529293A JP 2012514976 A JP2012514976 A JP 2012514976A JP 2012514976 A JP2012514976 A JP 2012514976A JP 2012529293 A JP2012529293 A JP 2012529293A
Authority
JP
Japan
Prior art keywords
peptide
seq
cells
motif
terminus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012514976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012529293A5 (enExample
Inventor
クレイグ ボンド ヴィンセント
パウエル マイケル
ボー フアン ミン
アリ シィェド
ディー． レイモンド アンドレア
ネヴィル シェルトン マーティン
ジャン ヴィリンジャー フランソワ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morehouse School of Medicine
Original Assignee
Morehouse School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morehouse School of Medicine filed Critical Morehouse School of Medicine
Publication of JP2012529293A publication Critical patent/JP2012529293A/ja
Publication of JP2012529293A5 publication Critical patent/JP2012529293A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2012514976A 2009-06-12 2010-05-21 微粒子の分泌を阻害することによりエイズまたは癌を治療することを目的とした組成物および方法 Ceased JP2012529293A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21347109P 2009-06-12 2009-06-12
US61/213,471 2009-06-12
US12/783,829 US8431530B2 (en) 2009-06-12 2010-05-20 Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
US12/783,829 2010-05-20
PCT/US2010/035698 WO2010144231A2 (en) 2009-06-12 2010-05-21 Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles

Publications (2)

Publication Number Publication Date
JP2012529293A true JP2012529293A (ja) 2012-11-22
JP2012529293A5 JP2012529293A5 (enExample) 2013-01-24

Family

ID=43306940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012514976A Ceased JP2012529293A (ja) 2009-06-12 2010-05-21 微粒子の分泌を阻害することによりエイズまたは癌を治療することを目的とした組成物および方法

Country Status (6)

Country Link
US (5) US8431530B2 (enExample)
EP (1) EP2440570B1 (enExample)
JP (1) JP2012529293A (enExample)
CN (1) CN102482325B (enExample)
CA (1) CA2761121A1 (enExample)
WO (1) WO2010144231A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528674A (ja) * 2016-09-30 2019-10-17 セレックス ライフ サイエンシズ，インコーポレーテッド タンパク質をロードしたエキソソームを含む組成物、並びにその調製及び送達のための方法
US11872193B2 (en) 2015-05-04 2024-01-16 Ilias Biologics Inc. Compositions containing protein loaded exosome and methods for preparing and delivering the same

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12083158B2 (en) 2011-10-07 2024-09-10 Morehouse School Of Medicine Antibacterial compositions, methods of making and use thereof
WO2013052058A1 (en) * 2011-10-07 2013-04-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
US8669226B2 (en) 2011-10-07 2014-03-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
EP2790735A4 (en) * 2011-12-13 2015-12-09 Ohio State Innovation Foundation METHODS AND COMPOSITIONS RELATING TO MIR-21 AND MIR-29A, EXOSOME INHIBITION, AND CANCER METASTASIS
US10800817B2 (en) 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
US10040831B2 (en) * 2016-12-19 2018-08-07 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
JP7348072B2 (ja) 2017-06-01 2023-09-20 コンピュジェン リミテッド 三重併用抗体療法
WO2020081634A2 (en) * 2018-10-16 2020-04-23 George Mason Research Foundation, Inc. Compositions and methods for modulation of extracellular vesicle release and treatment of neurological disorders
US11180534B1 (en) 2021-06-04 2021-11-23 Morehouse School Of Medicine Compositions and methods for treating SARS-CoV-2 infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229906A1 (en) * 2002-04-15 2003-12-11 Gelman Irwin H. Methods and compositions for the treatment of disorders of HIV infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040165A2 (en) * 2000-10-19 2003-05-15 Epimmune Inc. Hla class i and ii binding peptides and their uses
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
CN101675993A (zh) 2003-03-26 2010-03-24 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229906A1 (en) * 2002-04-15 2003-12-11 Gelman Irwin H. Methods and compositions for the treatment of disorders of HIV infection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6014022457; Ｊ．　Ｖｉｒｏｌ． ７４　（４）, 2000, ｐ．１６９４-１７０３ *
JPN6014022459; Ｉｎｔ．　Ｉｍｍｕｎｏｐｈａｒｍａｃｏｌ． ９, 200904, ｐ．４６８-４７７ *
JPN6014022460; Ｊ．　Ｂｉｏｌ．　Ｃｈｅｍ． ２８４　（１４）, 200904, ｐ．９１８４-９１９１ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11872193B2 (en) 2015-05-04 2024-01-16 Ilias Biologics Inc. Compositions containing protein loaded exosome and methods for preparing and delivering the same
JP2019528674A (ja) * 2016-09-30 2019-10-17 セレックス ライフ サイエンシズ，インコーポレーテッド タンパク質をロードしたエキソソームを含む組成物、並びにその調製及び送達のための方法

Also Published As

Publication number Publication date
WO2010144231A2 (en) 2010-12-16
WO2010144231A3 (en) 2011-04-21
US8871708B2 (en) 2014-10-28
US20140005117A1 (en) 2014-01-02
CN102482325A (zh) 2012-05-30
HK1167662A1 (en) 2012-12-07
US20130018002A1 (en) 2013-01-17
US20130018003A1 (en) 2013-01-17
US20100317566A1 (en) 2010-12-16
US8431530B2 (en) 2013-04-30
CN102482325B (zh) 2015-01-07
US8563506B2 (en) 2013-10-22
EP2440570A4 (en) 2012-04-18
US8551943B2 (en) 2013-10-08
US20140121170A2 (en) 2014-05-01
US8476237B2 (en) 2013-07-02
EP2440570A2 (en) 2012-04-18
CA2761121A1 (en) 2010-12-16
EP2440570B1 (en) 2013-08-14
US20130123202A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
CN102482325B (zh) 通过抑制微粒的分泌治疗aids或癌症的组合物和方法
KR102848852B1 (ko) 폴리펩티드, 이의 제조방법 및 용도
US20030077826A1 (en) Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
EP1012603B1 (en) Functional fragments of hiv-1 vpr protein and methods of using the same
Marrero-Hernández et al. HIV-1 nef targets HDAC6 to assure viral production and virus infection
US20210206811A1 (en) Cell-Penetrating Peptides and Methods of Use Thereof
CN108727475B (zh) 强效抑制hiv的脂肽、其衍生物、其药物组合物及其用途
Li et al. Molecular mechanisms in the dramatic enhancement of HIV-1 Tat transduction by cationic liposomes
Lin et al. Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancer
EP0689586A1 (en) Vpr function and activity
HK1167662B (en) Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
WO2001090159A2 (en) Compositions and methods for delivery of a molecule into a cell
Huang et al. Interaction of HIV-1 gp41 core with NPF motif in Epsin: implication in endocytosis of HIV
US6818627B1 (en) Functional fragments of HIV-1 Vpr protein and methods of using the same
JP2024512088A (ja) フィブリルペプチド
KR20250016568A (ko) Scotin 단백질의 항-코로나 바이러스제 용도
Valenzuela Fernández et al. HIV-1 Nef Targets HDAC6 to Assure Viral Production and Virus Infection.
CA2497890A1 (en) A mechanism for hiv-1 entry into host cells and peptides inhibiting this mechanism

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140809

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150317

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20150818